Rogers L, Barani I, Chamberlain M, etal. Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. J Neurosurg 2015;122:-23. doi: 10.3171/2014.7.JNS131644 pmid: 25343186
Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015. Neuro Oncol 2018;20(suppl_4):-86. doi: 10.1093/neuonc/noy131 pmid: 30445539
Baldi I, Gruber A, Alioum A, etalGironde TSNC Registry Group. Descriptive epidemiology of CNS tumors in France: results from the Gironde Registry for the period 2000-2007. Neuro Oncol 2011;13:-8. doi: 10.1093/neuonc/nor120 pmid: 21980160
Klaeboe L, Lönn S, Scheie D, etal. Incidence of intracranial meningiomas in Denmark, Finland, Norway and Sweden, 1968-1997. Int J Cancer 2005;117:-1001. doi: 10.1002/ijc.21255 pmid: 15986431
Roland N, Kolla E, Baricault B, etal. Oral contraceptives with progestogens desogestrel or levonorgestrel and risk of intracranial meningioma: national case-control study. BMJ 2025;389:e083981.
Hoisnard L, Laanani M, Passeri T, etal. Risk of intracranial meningioma with three potent progestogens: A population-based case-control study. Eur J Neurol 2022;29:-9. doi: 10.1111/ene.15423 pmid: 35621369
Roland NN, A; Hoisnard, L; Zureik, M; Weill, A. Utilisation de progestatifs et risque de méningiome intracrânien:une étude cas-témoins à partir des données du système national des données de santé (SNDS) wwwepi-pharefr. 2023.
Weill A, Nguyen P, Labidi M, etal. Use of high dose cyproterone acetate and risk of intracranial meningioma in women: cohort study. BMJ 2021;372:. doi: 10.1136/bmj.n37 pmid: 33536184
Roland N, Nguyen P, Neumann A, etal. Prolonged use of chlormadinone acetate and risk of intracranial meningioma: A population-based cohort study. Eur J Neurol 2025;32:e16505. doi: 10.1111/ene.16505 pmid: 39503288
Nguyen P, Roland N, Neumann A, etal. Prolonged use of nomegestrol acetate and risk of intracranial meningioma: a population-based cohort study. Lancet Reg Health Eur 2024;42:100928. doi: 10.1016/j.lanepe.2024.100928 pmid: 38800110
Malaizé H, Samoyeau T, Zanello M, etal. Evolution of the neurosurgical management of progestin-associated meningiomas: a 23-year single-center experience. J Neurooncol 2021;152:-88. doi: 10.1007/s11060-021-03696-9 pmid: 33449307
Kerschbaumer J, Freyschlag CF, Stockhammer G, etal. Hormone-dependent shrinkage of a sphenoid wing meningioma after pregnancy: case report. J Neurosurg 2016;124:-40. doi: 10.3171/2014.12.JNS142112 pmid: 26162042
Bernat AL, Oyama K, Hamdi S, etal. Growth stabilization and regression of meningiomas after discontinuation of cyproterone acetate: a case series of 12 patients. Acta Neurochir (Wien) 2015;157:-6. doi: 10.1007/s00701-015-2532-3 pmid: 26264069
Passeri T, Champagne P-O, Bernat A-L, etal. Spontaneous regression of meningiomas after interruption of nomegestrol acetate: a series of three patients. Acta Neurochir (Wien) 2019;161:-5. doi: 10.1007/s00701-019-03848-x pmid: 30783806
Lebeau J, Deprez L, Pintiaux A, Reuter G. Petroclival meningioma regression after combined oestrogen and nomegestrol acetate interruption. BMJ Case Rep 2025;18:e263529. doi: 10.1136/bcr-2024-263529 pmid: 39828291
Reuter G, Potorac I, de Herdt C, etal. Recommendations on the management of meningioma and sex hormone therapy: The results of a collaborative effort between neurosurgical, endocrine and gynecological societies. Brain Spine 2024;5:104154. doi: 10.1016/j.bas.2024.104154 pmid: 39802864
Graillon T, Boissonneau S, Appay R, etal. Meningiomas in patients with long-term exposition to progestins: Characteristics and outcome. Neurochirurgie 2021;67:-63. doi: 10.1016/j.neuchi.2021.04.018 pmid: 33989642
